Actimo Labs Pty Ltd (ACN 682 666 495)
3694
Total Complexes
200+
Hours Saved
47%
of Wet-Lab Cost
15M
Trained Total Residues
How will Epitope data help you?
Lead Candidate Selection
Lorem ipsum
Cost Effective Drug Development
Lorem ipsum
Strengthen IP Protection
Lorem ipsum
Safer Antibodies to market
Lorem Ipsum
"I love Actimo Labs, they're the best!"
Misty Jenkins
Professor & AO Lab Head at Walter and Eliza Hall Institute of Medical Research
How do we achieve >90% accuracy with AI?
Wow so lorem ipsum
Amazing aI
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
GOAT team
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
insane ideas
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
work - lots and lots of it
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Frequently Asked Questions
Have questions about how we can accelerate your antibody's preclinical development? Explore our FAQs below for quick answers.
How does Actimodel work?
By using your sequence and structure data, we will annotate your antibody, map the binding sites on the antibody and the antigen, conduct similarity tests, and rank the affinity of binding sites in our comprehensive off-target screen reports.
When will Actimodel launch?
Our Epitope Mapping services will be available in late January 2025. Full in silico Off-Target Screens will launch in Q3 2025. Join our newsletter to stay up to date with product and feature releases.
How can I engage with your services now?
We are currently partnered with the Brain Cancer Immunotherapy Lab at the Walter Eliza Hall Institute to refine our technology.
If you are a clinical researcher or computational biologist who could benefit from our services, please reach out to us to discuss how we can help your antibody get to market quicker.
Still have a question?
Speak to a member of our team below.